Department of Radiation Oncology, Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.
Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Clin Cancer Res. 2023 May 1;29(9):1648-1650. doi: 10.1158/1078-0432.CCR-23-0018.
Isocitrate dehydrogenase 1-mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radioresistance for IDH1m gliomas, and pharmacologic targeting of this pathway may heighten radiotherapy-induced tumor response, providing a prospect of improved clinical outcomes. See related article by Carney et al., p. 1763.
异柠檬酸脱氢酶 1 突变型 (IDH1m) 胶质瘤是一种难以治疗的肿瘤,放疗仍然是其标准治疗方法。最近的一项研究确定 ZMYND8 是 IDH1m 胶质瘤放射抵抗的关键介质,该途径的药物靶向可能会增强放疗诱导的肿瘤反应,从而提供改善临床结果的前景。见 Carney 等人的相关文章,第 1763 页。